Vinyl acetate: Carcinogenic Potency Database

Vinyl acetate (CAS 108-05-4)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
liv nas thy	liv nas thy ute	no positive	eso orc sto ute	341^m,v	3920

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: eso = esophagus. liv = liver. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). sto = stomach. thy = thyroid gland. ute = uterus. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD₅₀ values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Vinyl acetate: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



VINYL ACETATE   108-05-4
6466 M f cd1 inh 52w52 2167m                         0    55.3mg  221.mg  664.mg                      Bogdanffy;faat,23,215-229;1994
 lun tum kr     no dre   P=1.       21.4mg n.s.s.   0/10    0/10    0/10    0/10
6467 M f cd1 inh 70w86 2167n                         0    45.1mg  180.mg  541.mg
 lun tum kr     no dre   P=1.       47.6mg n.s.s.   0/10    0/10    0/10    0/10
6468 M f cd1 inh 82w82 2167o                         0    55.3mg  221.mg  664.mg
 lun tum kr     no dre   P=1.       53.2mg n.s.s.   0/10    0/10    0/10    0/10
6469 M f cd1 inh 24m24 2167r                         0    55.3mg  221.mg  664.mg
 lun tum r      no dre   P=1.       513.mg n.s.s.   0/60    0/60    0/60    0/60
6470 M m cd1 inh 52w52 2167m                         0    46.1mg  184.mg  554.mg
 lun tum kr     no dre   P=1.       17.8mg n.s.s.   0/10    0/10    0/10    0/10
6471 M m cd1 inh 70w85 2167n                         0    38.0mg  152.mg  456.mg
 lun tum kr     no dre   P=1.       39.2mg n.s.s.   0/10    0/10    0/10    0/10
6472 M m cd1 inh 82w82 2167o                         0    46.1mg  184.mg  554.mg
 lun tum kr     no dre   P=1.       44.3mg n.s.s.   0/10    0/10    0/10    0/10
6473 M m cd1 inh 24m24 2167r                         0    46.1mg  184.mg  554.mg
 lun sqc r      32.0gm * P<.2       5.22gm n.s.s.   0/60    0/60    0/60    1/60
 lun adc r      no dre   P=1.       428.mg n.s.s.   1/60    0/60    0/60    0/60
6474 M f swi wat 18m35 BT52                          0    103.mg  578.mg                               Maltoni;anya,837,209-238;1997
 ute mal g      3.92gm * P<.005  +  1.70gm 39.6gm   1/37    2/37    8/37
 eso sqc g      5.64gm * P<.002  +  2.30gm 22.1gm   0/37    0/37    6/37
 for ama g      6.85gm * P<.003  +  2.60gm 36.8gm   0/37    0/37    5/37
 ute adc g      5.57gm * P<.03      2.09gm n.s.s.   1/37    2/37    6/37
 ton sqc g      8.76gm * P<.05   +  3.03gm n.s.s.   0/37    1/37    3/37
 for sqc g      11.7gm * P<.02   +  3.54gm n.s.s.   0/37    0/37    3/37
 lun mix g      7.64gm * P<.3       1.94gm n.s.s.   3/37    6/37    7/37
 lun ade g      11.7gm * P<.5       2.22gm n.s.s.   3/37    6/37    6/37
 ute ley g      26.1gm * P<.4       4.67gm n.s.s.   1/37    0/37    2/37
 ute lei g      26.1gm * P<.4       4.67gm n.s.s.   1/37    0/37    2/37
 lun adc g      29.9gm * P<.5       4.50gm n.s.s.   0/37    1/37    1/37
 zym car g      36.0gm * P<.2       5.86gm n.s.s.   0/37    0/37    1/37
 orc sqc g      36.0gm * P<.2       5.86gm n.s.s.   0/37    0/37    1/37
 sto adc g      36.0gm * P<.2       5.86gm n.s.s.   0/37    0/37    1/37
 eso ama g      36.0gm * P<.2       5.86gm n.s.s.   0/37    0/37    1/37
 liv hpc g      no dre   P=1.       1.41gm n.s.s.   0/37    0/37    0/37
 tba ben g      2.03gm * P<.03      851.mg n.s.s.  12/37   10/37   20/37
 tba mal g      3.44gm * P<.5       680.mg n.s.s.  21/37   28/37   26/37
6475 M m swi wat 18m31 BT52                          0    96.3mg  546.mg
 lun ade        5.75gm * P<.6       852.mg n.s.s.   2/14    2/13    3/13
 for ama        9.33gm * P<.2       1.52gm n.s.s.   0/14    0/13    1/13
 orc sqc        9.33gm * P<.2       1.52gm n.s.s.   0/14    0/13    1/13
 sto adc        9.33gm * P<.2       1.52gm n.s.s.   0/14    0/13    1/13
 ton sqc        9.33gm * P<.2       1.52gm n.s.s.   0/14    0/13    1/13
 lun mix        28.0gm * P<1.       778.mg n.s.s.   4/14    4/13    4/13
 lun adc        68.2gm * P<1.       1.12gm n.s.s.   2/14    2/13    2/13
 liv hpc        no dre   P=1.       1.21gm n.s.s.   3/14    4/13    2/13
 tba mal        552.mg * P<.04      191.mg n.s.s.   7/14    6/13   11/13
 tba ben        6.04gm * P<.7       676.mg n.s.s.   5/14    3/13    5/13
6476 R f cdr inh 52w52 2167m                         0    13.2mg  52.7mg  158.mg                      Bogdanffy;faat,23,215-229;1994
 lun tum kr     no dre   P=1.       5.09mg n.s.s.   0/10    0/10    0/10    0/10
6477 R f cdr inh 70w86 2167n                         0    10.7mg  42.9mg  129.mg
 lun tum kr     no dre   P=1.       11.3mg n.s.s.   0/10    0/10    0/10    0/10
6478 R f cdr inh 82w82 2167o                         0    13.2mg  52.7mg  158.mg
 lun tum kr     no dre   P=1.       12.7mg n.s.s.   0/10    0/10    0/10    0/10
6479 R f cdr inh 24m24 2167r                         0    13.2mg  52.7mg  158.mg
 nse sqc er     2.22gm * P<.005  +  767.mg 18.2gm   0/60    0/60    0/60    4/59
 lar sqc er     9.05gm * P<.2       1.47gm n.s.s.   0/60    0/60    0/60    1/59
 lun ade er     no dre   P=1.       122.mg n.s.s.   1/60    0/60    0/60    0/59
6480 R m cdr inh 52w52 2167m                         0    9.23mg  36.9mg  111.mg
 lun tum kr     no dre   P=1.       3.56mg n.s.s.   0/10    0/10    0/10    0/10
6481 R m cdr inh 70w85 2167n                         0    7.60mg  30.4mg  91.2mg
 lun tum kr     no dre   P=1.       7.84mg n.s.s.   0/10    0/10    0/10    0/10
6482 R m cdr inh 82w82 2167o                         0    9.23mg  36.9mg  111.mg
 lun tum kr     no dre   P=1.       8.86mg n.s.s.   0/10    0/10    0/10    0/10
6483 R m cdr inh 24m24 2167r                         0    9.23mg  36.9mg  111.mg
 nse mix er     758.mg * P<.0005 +  343.mg 2.31gm   0/59    0/60    1/59    7/59
 nse ben er     1.24gm * P<.005  +  469.mg 10.4gm   0/59    0/60    1/59    4/59
 nse pai er     1.55gm * P<.005     535.mg 12.9gm   0/59    0/60    0/59    4/59
 nse mal er     2.08gm * P<.02   +  629.mg n.s.s.   0/59    0/60    0/59    3/59
 nse sqc er     3.14gm * P<.05      771.mg n.s.s.   0/59    0/60    0/59    2/59
 nse cic er     6.31gm * P<.2       1.03gm n.s.s.   0/59    0/60    0/59    1/59
 lun tum er     no dre   P=1.       84.5mg n.s.s.   0/58    0/59    0/60    0/60
 nse sqp er     no dre   P=1.       1.04gm n.s.s.   0/59    0/60    1/59    0/59
6484 R f f34 wat 23m30 1546                          0    44.0mg  110.mg                      Lijinsky;txap,68,43-53;1983/pers.comm.
 thy cca        420.mg * P<.006  +  181.mg 4.68gm   0/20    2/20    5/20
 liv nnd        488.mg * P<.003  +  198.mg 2.31gm   0/20    0/20    6/20
 ute adc        494.mg * P<.006  +  201.mg 4.70gm   0/20    1/20    5/20
 thy ccr        25.5gm * P<1.    +  590.mg n.s.s.   1/20    0/20    1/20
 tba mix        no dre   P=1.       37.7mg n.s.s.  20/20   18/20   19/20
6485 R m f34 wat 23m30 1546                          0    27.5mg  68.1mg
 liv nnd        132.mg \ P<.02   +  45.4mg n.s.s.   0/20    4/20   (2/20)
 thy ccr        no dre   P=1.    +  254.mg n.s.s.   1/20    2/20    1/20
 tba mix        57.7mg * P<.3       14.8mg n.s.s.  18/20   16/20   20/20

Mutagenicity in Salmonella: negative
SMILES Code for Vinyl acetate: CC(=O)OC=C
InChI Code for Vinyl acetate: InChI=1/C4H6O2/c1-3-6-4(2)5/h3H,1H2,2H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Vinyl acetate:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007